Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-ROR1 CAR NK Cells
- Development stage
- Preclinical
- Lead developer
- Caribou Biosciences
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**Anti-ROR1 CAR NK Cells** are an investigational cell therapy consisting of natural killer (NK) cells genetically engineered to express a chimeric antigen receptor (CAR) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), a tumor-associated antigen overexpressed in various solid tumors and hematological malignancies. The CAR redirects NK cells to recognize and lyse ROR1-positive cancer cells in an MHC-independent manner, leveraging NK cells' innate cytotoxicity, enhanced persistence, and reduced risk of cytokine release syndrome compared to CAR-T cells. Developed for challenging indications like neuroblastoma, glioblastoma, and other ROR1-expressing solid tumors, this therapy is being explored in preclinical studies and early clinical combinations, such as with cytokine-secreting oncolytic viruses or IL-15 superagonists like N-803, to overcome immunosuppressive tumor microenvironments.[2][3][4]
- Other names
- anti-ROR1 CAR-NK cellsanti-ROR-1 CAR-NK cellsanti-ROR 1 CAR-NK cells
02
Targets
ROR1 (Receptor tyrosine kinase-like orphan receptor 1)
Beyond the preview
Go deeper on Anti-ROR1 CAR NK Cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anti-ROR1 CAR NK Cells.